Strengthening our position as leaders in the field of molecular biology with expertise in labeling and detection, Enzo Life Sciences now offers the CYTAG™ TotalCGH Labeling Kit for CGH+SNP arrays.
Array-based Comparative Genomic Hybridization (aCGH) is a well-established method for investigating copy number variations and is used to detect a variety of genomic gains and losses ranging from duplications and deletions, unbalanced translocations, and aneuploidies. CGH is a robust method to detect chromosomal abnormalities and enables rapid screening of the entire genome. In addition, single nucleotide polymorphism (SNP), variation at a single nucleotide in a genome, can also be examined on a CGH+SNP array. A CGH+SNP array enables detection of genomic aberrations associated with copy number variations, but in addition, it can also detect copy neutral aberrations, such as loss of heterozygosity (LOH) and uniparental disomy (UPD), on the same array.
Enzo Life Sciences’ CYTAG™ TotalCGH Labeling Kit contains a complete set of reagents to prepare and label DNA for hybridization to a CGH+SNP array. The kit is compatible with both CGH arrays and CGH+SNP arrays and includes the CYTAG™ CGH Labeling kit, restriction enzymes AluI and RsaI, and PCR & Gel Clean-up Columns.
Enzo’s well established CYTAG™ CGH Labeling kit is the industry leading DNA labeling kit for CGH arrays. Our proprietary labeling technology delivers low Derivative Log Ratio (DLR) scores, assuring more confident aberrant calls and fewer failed runs. In addition, the CYTAG™ CGH Labeling kit is compatible with the most common dye-based arrays and has been validated on multiple scanning platforms.
For more information, or to order the CYTAG™ TotalCGH Labeling Kit or other Enzo Life Sciences products, please visit us at www.enzolifesciences.com or call us at 1-800-942-0430.
Enzo Life Sciences, Inc. is a wholly owned subsidiary of Enzo Biochem, Inc. headquartered in Farmingdale, New York. Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products and services that meet the ever-changing and rapidly growing needs of healthcare. Underpinning Enzo Biochem’s technologies, platforms and products is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
Enzo Life Sciences, Inc. is a pioneer in labeling and detection technologies from genome to whole cell across research and diagnostic markets. We are focused on providing cost-effective, relevant and reliable solutions for life science research, drug development, and clinical research. We are organized to lead in the development, production, marketing, and sales of innovative research tools worldwide based on 40 years’ experience in building strong global market recognition and implementing outstanding operational capabilities.
New Product Release
Date: March 22nd 2016
For additional Information, please contact:
Kara Cannon, Global Head of Marketing
1-631-694-7070 x 145
